Titanium dioxide nanoparticles (TiO2-NP) are being increasingly used in cosmetics and pharmaceutical products. In view of
its widespread use, there is a strong demand to evaluate their potential adverse effects to man, particularly their genotoxic
effects. Although several studies have already addressed this issue, a conclusion about TiO2-NP safety has not been
reached yet. As part of a wider EU Joint Action, this work aims at characterizing the genotoxicity of four TiO2-NP (anatase,
rutile, and rutile/anatase), in human peripheral blood lymphocytes (PBL). The cytokinesis-block micronucleus (CBMN) assay
(OECD 487) was used to assess both genotoxicity and cytotoxicity, following exposure to several concentrations of each
NP (5-250 μg/mL), during 30h. Preliminary data indicate that the anatase and rutile TiO2-NP do not display clear doseresponse
genotoxic or cytotoxic effects in PBL. Non-toxic effects had been previously reported in PBL and other cell lines,
e.g., CHO and human lung cells, whereas genotoxicity had been found by others in human lymphoblastoid cells and in
bronchial epithelial cells. Whether the present findings contribute to demonstrate that TiO2-NP are not genotoxic or rather
reflect the insensitivity of PBL to the genotoxicity of these NPs is a question that needs to be clarified in future studies
